Literature DB >> 1611855

The postantibiotic suppressive effect of L-ofloxacin, an optically active isomer of ofloxacin.

K P Fu1, B Foleno, M E Rosenthale.   

Abstract

The postantibiotic suppressive effect (PAE) of L-ofloxacin was studied and compared with those of ciprofloxacin and norfloxacin. The PAE of L-ofloxacin was observed against all Gram-positive organisms tested: Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis. At the achievable serum concentrations L-ofloxacin showed a longer PAE than ciprofloxacin and norfloxacin. Exposure of organisms to 4 micrograms/ml of L-ofloxacin for 2 hr produced a 3.1 and 4.2 hr PAE for methicillin-sensitive and methicillin-resistant staphylococci, respectively. Against E. faecalis and S. epidermidis, the PAEs of L-ofloxacin were 1.9 and 1.6 hr, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1611855     DOI: 10.1016/0732-8893(92)90028-r

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes.

Authors:  S L Pendland; M Diaz-Linares; K W Garey; J G Woodward; S Ryu; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  L Licata; C E Smith; R M Goldschmidt; J F Barrett; M Frosco
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; W Ritz
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

Review 5.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

6.  In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin.

Authors:  K P Fu; B D Foleno; S C Lafredo; J M LoCoco; D M Isaacson
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 7.  Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides.

Authors:  G G Zhanel; W A Craig
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

Review 8.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.